RETEVMO vs SPRYCEL

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. RETEVMO and SPRYCEL are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	RETEVMO	SPRYCEL
Rating	New	72/100
Pharmacy pays	—	~$839.19 /30
Type	RX	RX
Active ingredient	SELPERCATINIB	DASATINIB
Manufacturer	Eli Lilly and Co	Bristol Myers Squibb
Dosage forms	Capsule, Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms	Lymphoid Leukemia, Myeloid Leukemia

retevmo sprycel

Rating

New

72/100

Pharmacy pays

—

~$839.19 /30

Type

Active ingredient

SELPERCATINIB

DASATINIB

Manufacturer

Eli Lilly and Co

Bristol Myers Squibb

Dosage forms

Capsule, Tablet

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms

Lymphoid Leukemia, Myeloid Leukemia

Frequently asked questions

What is the difference between Retevmo and Sprycel?

Retevmo contains Selpercatinib, while Sprycel contains Dasatinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.